| |
Overall, n = 115
|
ESBL+, n = 67
|
ESBL−, n = 48
|
|---|
| |
S
|
I
|
R
|
S
|
I
|
R
|
S
|
I
|
R
|
|---|
| |
n
|
%
|
n
|
%
|
n
|
%
|
n
|
%
|
n
|
%
|
n
|
%
|
n
|
%
|
n
|
%
|
n
|
%
|
|---|
|
AM
|
5
|
4.3
|
1
|
0.9
|
109
|
94.8
|
0
|
–
|
0
|
–
|
67
|
100.0
|
5
|
10.4
|
1
|
2.1
|
42
|
87.5
|
|
AMC
|
67
|
58.3
|
16
|
13.9
|
32
|
27.8
|
43
|
64.2
|
12
|
17.9
|
12
|
17.9
|
24
|
50.0
|
4
|
8.3
|
20
|
41.7
|
|
TZP
|
93
|
80.9
|
14
|
12.2
|
8
|
7.0
|
59
|
88.1
|
7
|
10.4
|
1
|
1.5
|
34
|
70.8
|
7
|
14.6
|
7
|
14.6
|
|
CAZ
|
62
|
53.9
|
1
|
0.9
|
52
|
45.2
|
31
|
46.3
|
1
|
1.5
|
35
|
52.2
|
31
|
64.6
|
0
|
–
|
17
|
35.4
|
|
CTX
|
34
|
29.6
|
0
|
0.0
|
81
|
70.4
|
0
|
0.0
|
0
|
0.0
|
67
|
100.0
|
34
|
70.8
|
0
|
–
|
14
|
29.2
|
|
FEPa
|
68
|
62.4
|
13
|
11.9
|
28
|
25.7
|
34
|
55.7
|
11
|
18.0
|
16
|
26.2
|
34
|
70.8
|
2
|
4.2
|
12
|
25.0
|
|
ETP
|
112
|
97.4
|
2
|
1.7
|
1
|
0.9
|
66
|
98.5
|
1
|
1.5
|
0
|
–
|
46
|
95.8
|
1
|
2.1
|
1
|
2.1
|
|
IPM
|
115
|
100.0
|
0
|
–
|
0
|
–
|
67
|
100.0
|
0
|
–
|
0
|
–
|
48
|
100.0
|
0
|
–
|
0
|
–
|
|
MEM
|
115
|
100.0
|
0
|
–
|
0
|
–
|
67
|
100.0
|
0
|
–
|
0
|
–
|
48
|
100.0
|
0
|
–
|
0
|
–
|
|
AN
|
113
|
98.3
|
1
|
0.9
|
1
|
0.9
|
67
|
100.0
|
0
|
–
|
0
|
–
|
46
|
95.8
|
1
|
2.1
|
1
|
2.1
|
|
GM
|
73
|
63.5
|
3
|
2.6
|
39
|
33.9
|
43
|
64.2
|
1
|
1.5
|
23
|
34.3
|
30
|
62.5
|
2
|
4.2
|
16
|
33.3
|
|
CIP
|
37
|
32.2
|
1
|
0.9
|
77
|
67.0
|
17
|
25.4
|
1
|
1.5
|
49
|
73.1
|
20
|
41.7
|
0
|
–
|
28
|
58.3
|
- AMC: Amoxicillin/Clavulanic acid; TZP: Piperacillin/Tazobactam; ESBL: extended spectrum beta lactamase; CTX: Cefotaxime; CAZ: Ceftazidime; FEP: Cefepime; AN: Amikacin; CIP: Ciprofloxacin; S: susceptible; I: intermediate; R: resistant
- amissing values for FEP susceptibility, n = 6 in ESBL-producers (ESBL+)
